Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Platelets in Chronic Myelogenous Leukemia

Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation

Leukemia volume 18, pages 1127–1137 (2004)Cite this article

Abstract

In this study, we examined the effect of thrombopoietin (TPO) on the aggregation of platelets from 40 patients with myeloproliferative disorders (MPDs), including 17 patients with chronic myelogenous leukemia in the chronic phase (CML-CP), 10 with polycythemia vera, 10 with essential thrombocythemia, and three with myelofibrosis. TPO by itself dose-dependently induced the aggregation of platelets from patients with CML-CP but not from those with other MPDs or with CML-CP in cytogenetical complete remission. The expression of CD63 in CML-CP platelets was induced by TPO treatment. Phosphatidylinositol 3-kinase (PI3-kinase) was constitutively activated in CML-CP platelets. Pretreatment with PI3-kinase inhibitors (wortmannin and LY294002) dose-dependently inhibited TPO-induced aggregation of CML-CP platelets. The Abl kinase inhibitor imatinib mesylate and the Jak inhibitor AG490 suppressed TPO-induced aggregation of CML-CP platelets. Pretreatment with imatinib mesylate, but not with AG490, inhibited the activity of PI3-kinase in CML-CP platelets. In addition, tyrosine phosphorylation of Jak2 was undetected in CML-CP platelets before TPO treatment. These findings indicate that the constitutive activation of PI3-kinase primes CML-CP platelets for the aggregation induced by TPO, and that Bcr-Abl, but not Jak family protein tyrosine kinases, are involved in the constitutive activation of PI3-kinase in CML-CP platelets.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA et al. Stimulation of megakaryocytopoieis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533–538.

    Article  CAS  Google Scholar 

  2. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565–568.

    Article  CAS  Google Scholar 

  3. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M et al. c-Mpl ligand is a humoral regulator of megakaryopoiesis. Nature 1994; 369: 571–574.

    Article  CAS  Google Scholar 

  4. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117–1124.

    Article  CAS  Google Scholar 

  5. Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1995; 353: 57–61.

    Article  Google Scholar 

  6. Mathia N, Louache F, Vainchenker W, Wendling F . Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395–1401.

    Google Scholar 

  7. Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T . Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541–1545.

    Article  CAS  Google Scholar 

  8. Kubota Y, Arai T, Tanaka T, Yamaoka G, Kiuchi H, Kajikawa T et al. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 1996; 14: 439–444.

    Article  CAS  Google Scholar 

  9. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G . Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762–2768.

    CAS  PubMed  Google Scholar 

  10. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664–4670.

    CAS  PubMed  Google Scholar 

  11. Hofmann WK, Ottmann OG, Hoelzer D . Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Leukemia 1999; 13: 14–18.

    Article  CAS  Google Scholar 

  12. Kaushansky K . Use of thrombopoietic growth factors in acute leukemia. Leukemia 2000; 14: 505–508.

    Article  CAS  Google Scholar 

  13. Kuter DJ, Begley CG . Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457–3469.

    Article  CAS  Google Scholar 

  14. Wehmeier A, Sudhoff T, Meierkord F . Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23: 391–402.

    Article  CAS  Google Scholar 

  15. Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996; 88: 4304–4313.

    CAS  PubMed  Google Scholar 

  16. Moliterno AR, Hankins WD, Spivak JL . Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338: 572–580.

    Article  CAS  Google Scholar 

  17. Le Blanc K, Andersson P, Samuelsson J . Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. Br J Haematol 2000; 108: 80–85.

    Article  CAS  Google Scholar 

  18. Tefferi A, Yoon SY, Li CY . Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 2000; 96: 771–772.

    CAS  PubMed  Google Scholar 

  19. Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031–4038.

    CAS  PubMed  Google Scholar 

  20. Kiladjian JJ, Elkassar N, Hetet G, Briere J, Grandchamp B, Gardin C . Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia 1997; 11: 1821–1826.

    Article  CAS  Google Scholar 

  21. Ezumi Y, Takayama H, Okuma M . Thrombopoietin, a c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995; 374: 48–52.

    Article  CAS  Google Scholar 

  22. Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995; 86: 23–27.

    CAS  PubMed  Google Scholar 

  23. Rodriguez-Linares B, Watson SP . Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J 1996; 316: 93–98.

    Article  CAS  Google Scholar 

  24. Usuki K, Iki S, Endo M, Izutsu K, Inoue K, Nishimura T et al. Influence of thrombopoietin on platelet activation in myeloproliferative disorders. Br J Haematol 1997; 97: 530–537.

    Article  CAS  Google Scholar 

  25. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590–603.

    Article  CAS  Google Scholar 

  26. Lee Jr JT, McCubrey JA . The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16: 486–507.

    Article  CAS  Google Scholar 

  27. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1–8.

    Article  CAS  Google Scholar 

  28. Vazquez F, Sellers WR . The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000; 1470: M21–M35.

    CAS  PubMed  Google Scholar 

  29. Rittenhouse SE . Phosphoinositide 3-kinase activation and platelet function. Blood 1996; 88: 4401–4414.

    CAS  PubMed  Google Scholar 

  30. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J . Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054–4062.

    CAS  PubMed  Google Scholar 

  31. Pasquet JM, Gross BS, Gratacap MP, Quek L, Pasquet S, Payrastre B et al. Thrombopoietin potentiates collagen receptor signaling in platelets through a phosphatidylinositol 3-kinase-dependent pathway. Blood 2000; 95: 3429–3434.

    CAS  PubMed  Google Scholar 

  32. Zauli G, Bassini A, Vitale M, Gibellini D, Celeghini C, Caramelli E et al. Thrombopoietin enhances the alpha IIb beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood 1997; 89: 883–895.

    CAS  PubMed  Google Scholar 

  33. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645–648.

    Article  CAS  Google Scholar 

  34. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  Google Scholar 

  35. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938–1942.

    Article  CAS  Google Scholar 

  36. La Rosee P, O'Dwyer ME, Druker BJ . Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213–1219.

    Article  CAS  Google Scholar 

  37. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S . Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 284–294.

    Article  CAS  Google Scholar 

  38. Kubota Y, Tanaka T, Kitanaka A, Ohnishi H, Okutani Y, Waki M et al. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase. EMBO J 2001; 20: 5666–5677.

    Article  CAS  Google Scholar 

  39. Kubota Y, Tanaka T, Yamaoka G, Yamaguchi M, Ohnishi H, Kawanishi K et al. Wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, inhibits erythropoietin-induced erythroid differentiation of K562 cells. Leukemia 1996; 10: 720–726.

    CAS  PubMed  Google Scholar 

  40. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151–6161.

    Article  CAS  Google Scholar 

  41. Best D, Pasquet S, Littlewood TJ, Brunskill SJ, Pallister CJ, Watson SP . Platelet activation via the collagen receptor GPVI is not altered in platelets from chronic myeloid leukaemia patients despite the presence of the constitutively phosphorylated adapter protein CrkL. Br J Haematol 2001; 112: 609–615.

    Article  CAS  Google Scholar 

  42. ten Bosch GJ, Kessler JH, Blom J, Joosten AM, Gambacorti-Passerini C, Melief CJ et al. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. Br J Haematol 1998; 103: 1109–1115.

    Article  CAS  Google Scholar 

  43. Vassbotn FS, Havnen OK, Heldin CH, Holmsen H . Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha-receptor. J Biol Chem 1994; 269: 13874–13879.

    CAS  PubMed  Google Scholar 

  44. Grabarek J, Groopman JE, Lyles YR, Jiang S, Bennett L, Zsebo K et al. Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 1994; 269: 21718–21724.

    CAS  PubMed  Google Scholar 

  45. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia – potential clinical significance. Leukemia 2002; 16: 170–177.

    Article  CAS  Google Scholar 

  46. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995; 91: 661–663.

    Article  CAS  Google Scholar 

  47. Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 1996; 94: 5–16.

    Article  CAS  Google Scholar 

  48. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189–218.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Takeshi Arai for monitoring of the platelet aggregation, Novartis (Basel, Switzerland) for providing imatinib mesylate, and the Kirin Brewery Co. (Tokyo, Japan) for providing recombinant human thrombopoietin.

Author information

Authors and Affiliations

  1. The Department of Transfusion Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Y Kubota

  2. Environmental Health Sciences, Faculty of Medicine, Kagawa University, Kagawa, Japan

    T Tanaka

  3. The First Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    H Ohnishi, Y Okutani & T Ishida

  4. The Department of Laboratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    A Kitanaka & T Taminato

  5. Health Science Center of Kagawa University, Kagawa, Japan

    H Kamano

Authors
  1. Y Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Kitanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Okutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Taminato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Kamano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Kubota.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kubota, Y., Tanaka, T., Ohnishi, H. et al. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 18, 1127–1137 (2004). https://doi.org/10.1038/sj.leu.2403370

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403370

Keywords

This article is cited by

Search

Advanced search

Quick links